Answers are grounded in this paper and cite their sources.
A 24-year-old man with classical Hodgkin lymphoma was lost to follow-up after metabolic complete remission (mCR). He presented 4 years later with B-symptoms and impaired clinical condition. Relapsed classical Hodgkin lymphoma was diagnosed. PET/CT revealed stage IVB with liver and spleen involvement. Two liver function–adjusted salvage attempts were ineffective. Pembrolizumab was instituted with gradual clinical improvement. PET was missed before treatment for a life-threatening condition and was performed on day +10 showing a near mCR. A mCR was confirmed before cycle 2, on day +21, underlining—for the first time in the literature—the possibility to achieve very early mCR with pembrolizumab.
No takes yet. Share an insight, caveat, or question.
Georgopoulou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: